Healthcare provider profile · identity verified

Oscar Ray Wilson, MD

Family Practice · TYLER, TX · NPI 1245206937

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	797	232
Atorvastatin Calcium	Atorvastatin Calcium	787	232
Lisinopril	Lisinopril	472	128
Levothyroxine Sodium	Levothyroxine Sodium	405	118
Losartan Potassium	Losartan Potassium	341	111
Rosuvastatin Calcium	Rosuvastatin Calcium	252	82
Pantoprazole Sodium	Pantoprazole Sodium	201	59
Pravastatin Sodium	Pravastatin Sodium	190	60
Fluticasone Propionate	Fluticasone Propionate	183	61
Metoprolol Succinate	Metoprolol Succinate	177	56
Albuterol Sulfate Hfa	Albuterol Sulfate	176	59
Omeprazole	Omeprazole	174	58
Simvastatin	Simvastatin	168	52
Metformin Hcl Er	Metformin Hcl	165	61
Metformin Hcl	Metformin Hcl	151	43
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	146	18
Olmesartan Medoxomil	Olmesartan Medoxomil	142	43
Gabapentin	Gabapentin	141	41
Tamsulosin Hcl	Tamsulosin Hcl	137	44
Hydrochlorothiazide	Hydrochlorothiazide	103	35
Metoprolol Tartrate	Metoprolol Tartrate	101	30
Montelukast Sodium	Montelukast Sodium	98	32
Carvedilol	Carvedilol	92	33
Sertraline Hcl	Sertraline Hcl	85	31
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	83	25
Potassium Chloride	Potassium Chloride	82	29
Ozempic	Semaglutide	79	21
Escitalopram Oxalate	Escitalopram Oxalate	78	25
Allopurinol	Allopurinol	76	24
Azelastine Hcl	Azelastine Hcl	73	40
Duloxetine Hcl	Duloxetine Hcl	71	26
Tramadol Hcl	Tramadol Hcl	71	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	67	22
Donepezil Hcl	Donepezil Hcl	64	14
Glimepiride	Glimepiride	62	23
Pioglitazone Hcl	Pioglitazone Hcl	61	19
Ezetimibe	Ezetimibe	60	21
Finasteride	Finasteride	53	13
Trazodone Hcl	Trazodone Hcl	52	17
Alfuzosin Hcl Er	Alfuzosin Hcl	51	17
Furosemide	Furosemide	51	14
Synthroid	Levothyroxine Sodium	49	14
Alendronate Sodium	Alendronate Sodium	48	18
Bupropion Xl	Bupropion Hcl	47	13
Clopidogrel	Clopidogrel Bisulfate	45	14
Ramipril	Ramipril	42	12
Warfarin Sodium	Warfarin Sodium	42	31
Hydralazine Hcl	Hydralazine Hcl	41	11
Memantine Hcl	Memantine Hcl	41	14
Citalopram Hbr	Citalopram Hydrobromide	39	suppressed
Jardiance	Empagliflozin	39	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	38	16
Eliquis	Apixaban	36	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	36	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	12
Felodipine Er	Felodipine	33	suppressed
Lovastatin	Lovastatin	32	suppressed
Buspirone Hcl	Buspirone Hcl	31	13
Fluoxetine Hcl	Fluoxetine Hcl	31	12
Valsartan	Valsartan	30	suppressed
Pregabalin	Pregabalin	29	suppressed
Ondansetron Hcl	Ondansetron Hcl	26	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	25	suppressed
Irbesartan	Irbesartan	24	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	24	suppressed
Meloxicam	Meloxicam	24	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	23	suppressed
Mounjaro	Tirzepatide	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Trulicity	Dulaglutide	23	suppressed
Baclofen	Baclofen	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Risedronate Sodium	Risedronate Sodium	21	suppressed
Spironolactone	Spironolactone	21	11
Xarelto	Rivaroxaban	21	suppressed
Benazepril Hcl	Benazepril Hcl	20	suppressed
Glipizide	Glipizide	20	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	20	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Dutasteride	Dutasteride	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Telmisartan	Telmisartan	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	11
Candesartan Cilexetil	Candesartan Cilexetil	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Estradiol	Estradiol	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Mupirocin	Mupirocin	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Topiramate	Topiramate	15	suppressed
Atenolol	Atenolol	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	13	suppressed
Nystatin	Nystatin	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Famotidine	Famotidine	12	suppressed
Jantoven	Warfarin Sodium	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Metolazone	Metolazone	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Levemir	Insulin Detemir	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error